Share on StockTwits

Oppenheimer started coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued on Thursday, reports. The firm set an “outperform” rating on the stock.

Sarepta Therapeutics (NASDAQ:SRPT) traded down 6.93% on Thursday, hitting $21.34. 1,434,587 shares of the company’s stock traded hands. Sarepta Therapeutics has a 52-week low of $12.12 and a 52-week high of $55.61. The stock’s 50-day moving average is $26.32 and its 200-day moving average is $28.22. The company’s market cap is $868.1 million.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.75) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.80) by $0.05. The company had revenue of $6.09 million for the quarter, compared to the consensus estimate of $3.45 million. During the same quarter last year, the company posted ($0.41) earnings per share. Sarepta Therapeutics’s revenue was up 36.0% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics will post $-3.10 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a “positive” rating on shares of Sarepta Therapeutics in a research note on Wednesday. Separately, analysts at WBB Securites upgraded shares of Sarepta Therapeutics from a “speculative buy” rating to a “buy” rating in a research note on Tuesday. Finally, analysts at WBB Securities raised their price target on shares of Sarepta Therapeutics to $25.00 in a research note on Tuesday. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $38.14.

Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of rare and infectious diseases.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.